Abstract
Background:
Patients with systemic lupus erythematosus (SLE) are at increased risk of cardiovascular disease (CVD) compared to the general population. However, little is known about the effects of tobacco smoking on CVD in patients with SLE.
Objective:
To systematically review and summarize the available literature regarding the effects of tobacco smoking on developing CVD in patients with SLE.
Methods:
We retrieved relevant studies from the following databases: PubMed, EMBASE, Web of Science and China National Knowledge Internet (CNKI) database. Two reviewers independently reviewed the eligible studies, assessed their validity, and extracted relevant data. Sensitivity and subgroup analyses were performed to distinguish sources of heterogeneity.
Results:
A total of 10 studies, which comprised 6984 participants, were included in the analysis. The overall quality of evidence was rated as moderate to low. The smoking prevalence among CVD patients was 39.28% (271/690), which was higher than 31.36% (1974/6294) among non-CVD patients. Compared with never-smokers, the risk of developing CVD in current smokers was 1.42 (95% CI: 1.21–1.66). No significant publication bias was found in our meta-analysis.
Conclusions:
In spite of the several negative results, this study found that current smokers with SLE have an increased risk of developing CVD, although most of the included studies were in low-to-moderate quality.
Systematic Review Registration:
https://www.crd.york.ac.uk/prospero/, identifier CRD42022338109.
Introduction
Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease with variable presentations, course and prognosis. Worldwide, 20–150 out of every 100,000 people have SLE (1). Patient with SLE can suffer from clinical manifestations of multiple organs with substantial heterogeneity including arthritis, serositis, nephritis, gastrointestinal and neuropsychiatric problems (2).
A number of previous studies, both case-control and cohort designs, have indicated that SLE is associated with significantly greater CVD risk (3–5). Although the proportion of CVD events in SLE varies, an early study found that around 7% of SLE patients had a cardiovascular event (6). A more recent study from the UK Biobank demonstrated that SLE was associated with an almost 3-fold greater risk of CHD, over 4-fold greater risk of stroke, over 5-fold greater risk of venous thromboembolism (VTE), and an over 15-fold greater risk of peripheral arterial disease (PAD) (7). Therefore, the identification of potential risk factors to protect SLE patients from developing CVD needs careful exploration.
Tobacco smoking is one the most prevalent behaviors and a well-known risk factor associated with cardiovascular diseases, chronic obstructive pulmonary disease (COPD), cancers and diabetes (8, 9). However, little is known regarding the effects of tobacco smoking on developing CVD in patients with SLE. Thus, we conducted a systematic review and meta-analysis to investigate the effects of tobacco smoking on developing CVD in patients with SLE.
Methods and analysis
Study overview and registration
This systematic review and meta-analysis was conducted between December 2021 to May 2022, and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols statement guidelines (10). This study was registered on the PROSPERO (https://www.crd.york.ac.uk/prospero/) (CRD42022338109).
Literature search strategy
To identify relevant articles, the literature dated from the inception of the databases to December 2021 was searched in PubMed, EMBASE, Web of Science and China National Knowledge Internet (CNKI) databases, with no language restrictions.
The keywords and terms utilized in our research were: (systemic lupus erythematosus) AND (smoking or tobacco) AND (cardiovascular disease or heart disease or vascular disease or coronary artery disease or myocardial infarction, congestive heart failure or atherosclerosis). In addition, all references cited were reviewed to identify additional studies that were not included in the above-mentioned electronic databases.
Study selection
The literature was considered eligible based on the following inclusion criteria: (1) case-control studies or cohort studies; (2) the study provided the proportion of tobacco smoking in SLE patients with CVD and without CVD, respectively; (3) the SLE was diagnosed by international standards, such as the International Classification of Diseases (ICD), the American College of Rheumatology (ACR) standard of the American Society of Rheumatology; (4) all the participants were adults over the age of 18.
The literature was excluded based on the following criteria: (1) case reports, editorials, and reviews; (2) studies where the research subject was not human; (3) studies without control cases; (4) insufficient data or unpublished literature.
Two authors (LIU Z and HUANG C) conducted a comprehensive identification of included publications, independently. Disagreement was resolved through discussion or a third author (XUE CM).
Data extraction and quality assessment
We extracted the following information from the included study. Two authors (ZHANG WT, ZHU BC) independently extracted data using the standardized covidence data extraction form. A third review author provided a review of the quality assessment and a consensus check.
-
◼ Funding source
-
◼ Authors’ declarations of interest
-
◼ Country, authors and year of publication
-
◼ Research location
-
◼ Study design
-
◼ Inclusion criteria and exclusion criteria
-
◼ Number of participants
-
◼ Age and other relevant characteristics of study participants
-
◼ Proportion of current smokers in SLE patients with CVD
-
◼ Proportion of current smokers in SLE patients without CVD
The methodological quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS) (11), which was widely used for assessing the quality of observational studies in a meta-analysis, and was based on selection (4 items), comparability (1 item), and outcome (3 items).25 The star rating system of NOS ranged from 0–9, and a study with 7 stars is regarded as high quality.
Evaluation of heterogeneity and publication bias
To examine potential sources of heterogeneity observed in the meta-analysis, subgroup analysis was performed based on study region, SLE criteria, different study quality, and proportion of female in total study population. Begg test and Egger test were used to detect publication bias.
Statistical analysis
In this meta-analysis, Stata SE 16.0 software (StataCorp LP, USA) was used for statistical analysis. The results were reported as relative risk (RR) and 95% confidence interval (CI). The heterogeneity of the results from individual studies was analyzed by I-square statistics, and fixed effect model or random effect model was selected. When I2 > 50%, indicating there was heterogeneity, a random effect model was used to improve stability. Otherwise, a fixed effect model was used. Moreover, subgroup analyses were performed to evaluate the robustness of this meta-analysis. Begg test and Egger test were conducted to evaluate publication bias. All P values were calculated by double-tail.
Results
Database search results
The initial search was completed on June 1, 2021. We have identified 279 potentially relevant publications. Endnote software was used to eliminate duplicate publications, resulting in 242 records for review.
After excluding publications that did not meet the inclusion or meet the exclusion criteria, we included 10 studies (12–21) for systematic review and meta-Analysis. A flow diagram illustrating the exclusion of articles with specific reasons was shown in Figure 1.
Figure 1
The flow diagram of literature retrieval, screening and exclusion.
Study characteristics
The included 10 studies were all cross-sectional studies published between 2004 and 2016. The sample size varied from 57 to 3288, with a total of 6984 patients with SLE. In addition, 4 studies were conducted in Europe, and 6 in North America.
The methods for SLE assessment were consistent, including 6 studies with 1982 ACR criteria (22), and 4 studies with 1997 ACR criteria (23).
As planned, we used Newcastle-Ottawa Quality Assessment Scale (NOS) to evaluate the quality of the cross-sectional studies. Three studies (30%) were considered high quality and 7 studies (70%) were determined as low-to-moderate quality. The main characteristics of the 10 included studies are shown in Table 1.
Table 1
| First author | Year | Study population | Ethnicity | Region | Mean age | Female% | SLE criteria | NOS score | Total sample size | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Selection | Comparability | Outcome | |||||||||
| Selzer F (12) | 2004 | Women | White (90.7%) | US | 45.2 ± 10.5 | 100 | 1982 ACR criteria | ✵✵ | ✵ | ✵✵ | 214 |
| Toloza SM (13) | 2004 | General population | Hispanic, African-American and Caucasian | US | 36.5 ± 12.3 | 89.6 | 1982 ACR criteria | ✵✵ | ✵ | ✵✵ | 546 |
| Szalai AJ (14) | 2005 | General population | Hispanic, African-American and Caucasian | US | Not reported | 43.86 | 1982 ACR criteria | ✵ | ✵ | ✵✵ | 57 |
| Bertoli AM (15) | 2009 | General population | Texan Hispanics, Puerto Rican Hispanics, African Americans and Caucasians |
US | 35.7 ± 12.3 | 90.4 | 1997 ACR criteria | ✵✵ | ✵✵ | ✵✵✵ | 1314 |
| Gustafsson J (16) | 2009 | General population | European Caucasians Asian | Sweden | 45 (31-53) | 90 | 1982 ACR criteria | ✵✵✵ | ✵ | ✵✵✵ | 182 |
| Maureen McMahon (17) | 2009 | Women | Caucasian, Asian, Pacific Islander, African American, Hispanic, Mixed and Other | US | Not reported | 100 | 1997 ACR criteria | ✵✵ | ✵ | ✵✵ | 276 |
| Urowitz MB (18) | 2010 | General population | Caucasian, Black, Hispanic, Asian and other | Canada | 34.3 ± 13.3 | 89.4 | 1982 ACR criteria | ✵✵✵ | ✵ | ✵ | 637 |
| Fernández-Nebro (19) | 2015 | General population | Caucasian, Amerindian Caucasians, Black Africans, Asians, and others | Spanish | 45.0 (35.7–56.5) | 90.3 | 1997 ACR criteria | ✵✵ | ✵ | ✵✵ | 3288 |
| Gustafsson JT (20) | 2015 | General population | European Caucasians (90%) | Sweden | Not reported | 86 | 1982 ACR criteria | ✵✵ | ✵ | ✵✵ | 367 |
| Kay SD (21) | 2016 | General population | White (98%) | Denmark | 49.2 ± 14.1 | 89 | 1997 ACR criteria | ✵✵✵ | ✵✵ | ✵✵ | 103 |
The main characteristic of all included publications in this study.
ACR, American College of Rheumatology. According to NOS, a study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability.
Tobacco smoking and the risk of developing CVD
The smoking prevalence among CVD patients was 39.28% (271/690), which was higher than 31.36% (1974/6294) among non-CVD patients. Since the heterogeneity was found among these studies (I2 = 56%), the random effect model was applied for pooled analysis in this study. As a result, compared with never-smokers, the risk of developing CVD in current smokers was 1.59 (95% CI: 1.41–2.15). The forest plot for the relationship between tobacco smoking and developing CVD risk was shown in Figure 2.
Figure 2
Forest plot for effects of tobacco smoking on developing CVD in patients with SLE. systemic lupus erythematosus, SLE; cardiovascular disease, CVD.
Subgroup analysis
According to the study area, the diagnosis criteria of SLE, proportion of female, and quality of study, a subgroup analysis of 10 studies was conducted (Figure 3).
Figure 3
Subgroup analysis of tobacco smoking on developing CVD in patients with SLE. (A) forest plot according to the study area; (B) forest plot according to different SLE criteria; (C) forest plot according to study quality; (D) forest plot according to proportion of female participants. systemic lupus erythematosus, SLE; cardiovascular disease, CVD.
The Figure 3A, a comparison between the European area and North America area, showed that no matter where the region was, the smoking SLE patients had increased risk of developing CVD (for European area, RR=1.35, 95% CI: 1.13-1.61); for North America area, RR=1.87, 95% CI: 1.54-2.27). The Figure 3B, which was a comparison between 1982 ACR criteria and 1997 ACR criteria for SLE, showed that no matter what the diagnosis criteria was, the smoking SLE patients had increased risk of developing CVD (for 1982 ACR criteria, RR=1.61, 95% CI: 1.34-1.94); for 1997 ACR criteria, RR=1.54, 95% CI: 1.06-2.25).
The Figure 3C, a comparison between low-to-moderate study quality and high study quality, showed that no matter what the study quality, the smoking SLE patients had increased risk of developing CVD (for low-to-moderate study quality, RR=1.50, 95% CI: 1.21-1.87); for high study quality, RR=1.74, 95% CI: 1.416–2.15). The Figure 3D, a comparison between the all-female population and non-100% female population, showed that all-female population had no increased risk of developing CVD (RR=1.36, 95% CI: 0.76-2.43). It should be noted that only 15 smokers were included into this subgroup analysis.
Publication bias
The Egger linear regression test and Begg funnel chart were adopted to verify whether there was a publication bias in our meta-analysis. The result of Egger linear regression indicated that there was no statistically significant publication bias (P=0.531). The Begg test results also confirmed that there was no statistically significant publication bias (P=0.327). As such, no significant publication bias was found in our meta-analysis.
Discussion
To the best of our knowledge, this was the first systematic review and Meta-analysis to investigate the effects of tobacco smoking on risk of developing CVD in patients with SLE. Our findings indicated that current smokers with SLE have an increased risk of developing CVD, although most of the included studies were in low-to-moderate quality.
Tobacco smoking is an established risk factor of developing SLE. A large cohort study involving more than 238,000 women in the prospective Nurses’ Health Study indicated that current smokers had increased risk of developing SLE (24). A meta-analysis of seven case-control and two cohort studies found a significant risk for the development of SLE among current smokers compared to non-smokers (OR 1.50, 95% CI 1.09–2.08) (25). A later meta-analysis with newer studies confirmed this finding (26).
In the general population, nearly half of the premature mortality associated with smoking is due to CVD (27). Also, increased risk of premature CVD is well recognized in SLE (28). Therefore, it is important to summarize the effect of smoking on the risk of cardiovascular disease in patients with SLE. Based on the previous evidence, our study further showed that smoking could lead to greater risk of CVD in SLE. Although not surprising, there are several implications and considerations related to our findings. First, the detrimental effects of smoking on SLE should never be underestimated, and we believe that smoking cessation should be one of the primary concerns for physicians treating SLE, and must be a cornerstone of treatment. Second, the quality of the included studies was poor to moderate, particularly most of them had limitations on small sample size and non-representativeness study population, which could decrease reliability of the evidence and restrict the interpretation of these results. Third, with our preliminary data, we call for joint efforts to further explore the association between tobacco smoking and SLE, such as dose–effect relationship between higher smoking packyears and SLE, the detrimental effects of smoking on SLE treatment response, etc.
There are some limitations in this meta-analysis. First, as we mentioned above, the sample size of some included studies was relatively small. Second, due to the lack of relevant studies, secondhand smoking exposure were not explored. Third, the case-control studies included in our meta-analysis may inevitably suffer from several biases by their retrospective design. Finally, as a social phenomenon, tobacco smoking is linked to many confounding factors such as socioeconomic level, stress, bad health habits or lack of therapeutic adherence, which might compromise the findings of our study.
Conclusion
In spite of the several negative results, this study found that current smokers with SLE have an increased risk of developing CVD, although most of the included studies were in low-to-moderate quality. As such, smoking cessation should be one of the primary concerns for physicians treating SLE, and must be a cornerstone of treatment.
Funding
This study was supported by National Natural Science Foundation of China (82004352), Academic Inheritance Studio of Professor W-LW and China Fundamental Research Funds for Central Public Welfare Research Institutes (ZZ14-YQ-006).
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Author contributions
W-TZ, ZL, and B-CZ were involved in the methodological design of the systematic review, and conducted the acquisition of data, analyses, and interpretation. W-LW and G-DH directed and organized the systematic review and the methodologist team. FL and C-MX conducted data interpretation, and provided substantial feedback on the drafted manuscript. ZL and B-CZ wrote the manuscript and Q-YL revised the manuscript. All authors were involved in the planning of the study, literature review, interpretation of the findings, manuscript preparation and approved the final version before submission.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The reviewer ZM declared a shared parent affiliation with the author Z-YC to the handling editor at the time of review.
References
1
Mecacci F Pieralli A Bianchi B Paidas MJ . The impact of autoimmune disorders and adverse pregnancy outcome. Semin Perinatol (2007) 31(4):223–6. doi: 10.1053/j.semperi.2007.05.005
2
Durcan L O' Dwyer T Petri M . Management strategies and future directions for systemic lupus erythematosus in adults. Lancet (2019) 393(10188):2332–43. doi: 10.1016/S0140-6736(19)30237-5
3
Fischer LM Schlienger RG Matter C Jick H Meier CR . Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol (2004) 93(2):198–200. doi: 10.1016/j.amjcard.2003.09.037
4
Salvetti M Paini A Andreoli L Stassaldi D Aggiusti C Bertacchini F et al . Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences. Eur J Intern Med (2020) 73:76–82. doi: 10.1016/j.ejim.2019.12.001
5
Esdaile JM Abrahamowicz M Grodzicky T Li Y Panaritis C du Berger R et al . Traditional framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheumatol (2001) 44(10):2331–7. doi: 10.1002/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-i
6
Mak A Kow NY . Imbalance between endothelial damage and repair: a gateway to cardiovascular disease in systemic lupus erythematosus. BioMed Res Int (2014) 2014:178721. doi: 10.1155/2014/178721
7
Dregan A Chowienczyk P Molokhia M . Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic inflammatory disorders. Heart (2017) 103(23):1867–73. doi: 10.1136/heartjnl-2017-311214
8
Kondo T Nakano Y Adachi S Murohara T . Effects of tobacco smoking on cardiovascular disease. Circ J (2019) 83(10):1980–5. doi: 10.1253/circj.CJ-19-0323
9
Yang JJ Yu D Wen W Shu X-O Saito E Rahman S et al . Tobacco smoking and mortality in asia: A pooled meta-analysis. JAMA Netw Open (2019) 2(3):e191474. doi: 10.1001/jamanetworkopen.2019.1474
10
Shamseer L Moher D Clarke M Ghersi D Liberati A Petticrew M et al . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-p) 2015: elaboration and explanation [published correction appears in BMJ. BMJ (2015) 350:g7647. doi: 10.1136/bmj.g7647
11
Wells G Shea B and O’Connell D . The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute (2009). Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
12
Selzer F Sutton-Tyrrell K Fitzgerald SG Pratt JE Tracy RP Kuller LH et al . Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheumatol (2004) 50(1):151–9. doi: 10.1002/art.11418
13
Toloza SM Uribe AG McGwin G Jr Alarcón GS Fessler BJ Bastian HM et al . Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. baseline predictors of vascular events. Arthritis Rheumatol (2004) 50(12):3947–57. doi: 10.1002/art.20622
14
Szalai AJ Alarcón GS Calvo-Alén J Toloza SM McCrory MA Edberg JC et al . Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXX: association between c-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatol (Oxford) (2005) 44(7):864–8. doi: 10.1093/rheumatology/keh613
15
Bertoli AM Vilá LM Alarcón GS McGwin G Edberg JC Petri M et al . Factors associated with arterial vascular events in PROFILE: a multiethnic lupus cohort. Lupus (2009) 18(11):958–65. doi: 10.1177/0961203309104862
16
Gustafsson J Gunnarsson I Börjesson O Pettersson S Möller S Fei GZ et al . Predictors of the first cardiovascular event in patients with systemic lupus erythematosus- a prospective cohort study. Arthritis Res Ther (2009) 11(6):R186.
17
McMahon M Grossman J Skaggs B Fitzgerald J Sahakian L Ragavendra N et al . Dysfunctional pro-inflammatory high density lipoproteins confer increased risk for atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheumatol (2009) 60(8):2428–37. doi: 10.1002/art.24677
18
Urowitz MB Gladman D Ibañez D Bae SC Sanchez-Guerrero J Gordon C et al . Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 62(6):881–7. doi: 10.1002/acr.20122
19
Fernández-Nebro A Rúa-Figueroa Í López-Longo FJ Galindo-Izquierdo M Calvo-Alén J Olivé-Marqués A et al . Cardiovascular events in systemic lupus erythematosus: A nationwide study in spain from the relesser registry. Med (Baltimore) (2015) 94(29):e1183. doi: 10.1097/MD.0000000000001183
20
Gustafsson JT Gunnarsson IwwKällbergHPetterssonSZickertAVikerforsAet al. Cigarette smoking, antiphospholipid antibodies and vascular events in systemic lupus erythematosus. Ann Rheum Dis (2015) 74(8):1537–43. doi: 10.1136/annrheumdis-2013-205159
21
Kay SD Poulsen MK Diederichsen AC Voss A . Coronary, carotid, and lower-extremity atherosclerosis and their interrelationship in danish patients with systemic lupus erythematosus. J Rheumatol (2016) 43(2):315–22. doi: 10.3899/jrheum.150488
22
Tan EM Cohen AS Fries JF Masi AT McShane DJ Rothfield NF et al . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 25:1271–7. doi: 10.1002/art.1780251101
23
Hochberg MC . Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheumatol (1997) 40(9):1725. doi: 10.1002/art.1780400928
24
Barbhaiya M Tedeschi SK Lu B Malspeis S Kreps D Sparks JA et al . Cigarette smoking and the risk of systemic lupus erythematosus, overall and by anti-double stranded DNA antibody subtype, in the nurses' health study cohorts. Ann Rheum Dis (2018) 77(2):196–202. doi: 10.1136/annrheumdis-2017-211675
25
Costenbader KH Kim DJ Peerzada J Lockman S Nobles-Knight D Petri M et al . Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum (2004) 50(3):849–57. doi: 10.1002/art.20049
26
Jiang F Li S Jia C . Smoking and the risk of systemic lupus erythematosus: an updated systematic review and cumulative meta-analysis. Clin Rheumatol (2015) 34(11):1885–92. doi: 10.1007/s10067-015-3008-9
27
Bhatnagar A . Environmental determinants of cardiovascular disease. Circ Res (2017) 121(2):162–80. doi: 10.1161/CIRCRESAHA.117.306458
28
Hasni SA Gupta S Davis M Poncio E Temesgen-Oyelakin Y Carlucci PM et al . Phase 1 double-blind randomized safety trial of the janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun (2021) 12(1):3391. doi: 10.1038/s41467-021-23361-z
Summary
Keywords
systemic lupus erythematosus, tobacco smoking, cardiovascular disease, systematic review, meta-analysis
Citation
Zhang W-t, Liu Z, Zhu B-c, Cui Z-y, Huang C, Wang X-j, Lu F, Li Q-y, Weng W-l, Hua G-d and Xue C-m (2022) Effects of tobacco smoking on cardiovascular disease in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Front. Immunol. 13:967506. doi: 10.3389/fimmu.2022.967506
Received
13 June 2022
Accepted
30 June 2022
Published
27 July 2022
Volume
13 - 2022
Edited by
Jian Gao, Shanghai Children’s Medical Center, China
Reviewed by
Ranran Dai, Shanghai Jiao Tong University, China; Zhijie Ma, Capital Medical University, China
Updates
Copyright
© 2022 Zhang, Liu, Zhu, Cui, Huang, Wang, Lu, Li, Weng, Hua and Xue.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Wei-liang Weng, ww6488@126.com; Guo-dong Hua, zhaojhuagd@126.com; Chun-miao Xue, xuechunmiao9501@163.com
†These authors have contributed equally to this work
This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.